Evidence Hub

Alterations in Gut Microbiome Diversity and Composition in Patients with Epidermolysis Bullosa: A Case-Control Study

S. Widhiati, H. Soebono, Dewajani Purnomosari, T. Wibawa

Indian Journal of Dermatology, 2026

Abstract

Epidermolysis bullosa (EB) is a rare inherited genodermatosis that affects both the skin and gastrointestinal tract, potentially leading to altered gut microbiota. This study aimed to assess the diversity and composition of the gut microbiome in EB patients compared to healthy controls. Twelve EB patients—six with dystrophic epidermolysis bullosa patients (pDEB) and six with nondystrophic epidermolysis bullosa patients (pNDEB)—and 12 age- and gender-matched healthy controls were included. Fecal samples were collected, and 16S rRNA gene sequencing (V3–V4 region) was performed. Alpha diversity indices revealed a significant reduction in gut microbiota richness in EB patients, particularly in pNDEB, compared to controls. Beta diversity analysis using unweighted UniFrac showed compositional differences between groups, while weighted UniFrac and principal coordinate analysis revealed overlapping clustering patterns. Genus-level comparisons indicated lower relative abundance of Staphylococcus, Corynebacterium, and Prevotella in EB subgroups. These findings suggest that EB is associated with gut microbiota dysbiosis, warranting further investigation into its potential clinical implications and microbial biomarkers.

How strong is the evidence?

Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free